Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
RedHill Biopharma is an Israeli specialty biopharmaceutical company focused on gastrointestinal and infectious diseases, with commercial products including Talicia (H. pylori treatment approved in US), Aemcolo (travelers' diarrhea), and Movantik (opioid-induced constipation). The company operates in a capital-intensive development stage with negative cash flows, minimal revenue base (~$10-15M estimated annual run-rate), and is pursuing pipeline assets including opaganib for oncology/viral indications. Stock is driven by clinical trial readouts, regulatory milestones, and financing events given the severe liquidity constraints evident in the 0.56 current ratio.
RedHill generates revenue through direct commercial sales of three FDA-approved GI products in the US market, targeting specialty gastroenterology and infectious disease channels. The company lacks pricing power given competitive H. pylori treatment landscape (generic triple therapy alternatives) and niche indications with limited patient populations. Gross margins of 60% reflect typical pharmaceutical economics, but the company burns significant cash on clinical development (opaganib trials), commercial infrastructure, and debt servicing. The business model is currently unsustainable without external financing, as evidenced by negative operating cash flow exceeding revenue and deteriorating working capital position.
Opaganib clinical trial data releases (oncology and viral indication studies) - binary events with 30-50% single-day volatility potential
Financing announcements and dilution risk - equity raises, warrant exercises, or debt restructuring given negative working capital
FDA regulatory decisions or clinical hold resolutions affecting pipeline progression
Talicia market penetration metrics and formulary access wins/losses in US managed care
Partnership or licensing deals for commercial assets or pipeline programs to address liquidity crisis
Going concern risk - Current ratio of 0.56 and negative operating cash flow indicate company may not have sufficient liquidity to fund operations beyond 6-12 months without additional financing. Equity raises at current depressed valuation would be massively dilutive to existing shareholders.
Clinical trial failure risk for opaganib pipeline - Company has invested heavily in oncology and viral indication studies with binary outcomes. Failed trials would eliminate future value drivers and likely trigger strategic alternatives including asset sales or bankruptcy.
Generic competition erosion for Talicia - H. pylori treatment market faces pricing pressure from established generic triple therapy regimens, limiting commercial upside and pricing power for branded alternatives.
Talicia faces direct competition from generic clarithromycin-based triple therapy (costs <$50 vs. Talicia's ~$2,000+ list price), limiting market share to clarithromycin-resistant cases or patients failing first-line therapy
Aemcolo competes in small travelers' diarrhea prophylaxis market against generic azithromycin and fluoroquinolones with superior cost profiles and broader antimicrobial coverage
Large-cap GI pharma companies (AbbVie, Takeda) have substantially greater commercial reach and R&D resources for competitive pipeline development
Negative working capital and sub-1.0x current ratio indicate immediate liquidity crisis requiring near-term financing or asset monetization
Negative book value (Price/Book of -0.4x) suggests liabilities exceed assets, with potential debt covenant violations or restructuring needs
Accumulated deficit likely exceeds $300-400M based on years of cash burn, limiting future financing options and creating massive overhang for equity holders
low - Prescription pharmaceutical demand for GI conditions is relatively non-discretionary and insulated from economic cycles. However, the company's ability to raise capital is highly sensitive to biotech funding conditions and risk appetite in equity markets. Clinical-stage biotech financing dried up significantly during 2022-2023 market downturn, creating existential risk for cash-burning companies like RedHill.
High sensitivity through two channels: (1) Rising rates compress biotech valuations by increasing discount rates applied to distant cash flows from pipeline assets, disproportionately impacting pre-profitable companies. (2) Higher rates increase cost of debt financing and reduce availability of venture/growth capital for clinical-stage companies. The negative 204.8% ROE and -72.5% ROA indicate severe capital inefficiency, making equity dilution at depressed valuations likely in higher rate environments. Current debt structure and refinancing needs are material risks.
Minimal direct credit exposure from operations, but company faces severe credit stress itself. The -0.05 debt/equity ratio appears anomalous (likely negative equity), and 0.56 current ratio signals imminent liquidity crisis. Access to credit markets or structured financing is critical for survival, making credit spreads (BAMLH0A0HYM2) relevant for refinancing ability. Widening high-yield spreads would effectively shut off debt capital access.
High-risk speculative/momentum traders and biotech-focused funds willing to accept binary clinical trial outcomes and potential total loss. The -70.8% one-year return, negative cash flows, and liquidity crisis make this unsuitable for value or income investors. Attracts event-driven traders around clinical data catalysts and financing announcements. Institutional ownership likely minimal given micro-cap size and distressed fundamentals.
high - Clinical-stage biotech with minimal revenue, negative cash flows, and existential financing risk exhibits extreme volatility. Single-day moves of 20-40% common around trial data or financing news. Beta likely 2.0+ relative to broader biotech indices. The -23.3% three-month return demonstrates ongoing downward pressure from dilution fears and lack of positive catalysts.
